Clinical DevelopmentPhase 1b initiation marks next step in NXP900’s clinical development.
Financial StrategyDeprioritization of NXP800 frees time, resources, and capital better deployed in assets with a greater chance of success in the clinic and therapeutic potential in the long run.
Therapeutic PotentialNXP900 exhibits potent synergistic activity with osimertinib in both sensitive and resistant models, pointing to its versatility in cancer treatment strategies.